DCF Analysis Suggests 80% Upside, but DeepValue Report Flags Risks

What happened

A new DCF analysis from GuruFocus pegs Novo Nordisk's intrinsic value at $90 per share, implying over 80% upside from the current ~$49 price. However, the latest DeepValue Master Report maintains a WAIT rating with a base-case value of just $53, citing the need for proof that oral Wegovy script growth will convert into revenue rather than just low-price volume. The report highlights that while oral Wegovy prescriptions have surged past 3 million, US payer rebate escalation and Lilly's competitive oral launch threaten pricing and market share. Key catalysts in Q2-Q3 2026 include obesity revenue conversion, the Medicare GLP-1 Bridge impact, and REIMAGINE 4 data, which will determine if the stock can justify a higher multiple. The DCF optimistic view relies on assumptions about sustained high growth and margins that the DeepValue analysis views as uncertain given current competitive and pricing headwinds.

Implication

The DCF intrinsic value of $90 suggests significant upside, but the DeepValue report's WAIT rating reflects unresolved risks. Investors should not chase the stock solely on DCF; the market already prices in some recovery. The critical test is whether Q2/Q3 obesity revenue stabilizes despite oral mix shift. If scripts convert to revenue and pipeline milestones hit, the stock could re-rate toward $60. Until then, trim above $60 and look to add near $44 for a more favorable entry.

Thesis delta

The DCF introduces a bullish anchor of $90 intrinsic value, but it does not alter the DeepValue report's cautious view. The thesis remains WAIT, with the same re-assessment triggers: oral Wegovy revenue conversion, Medicare impact, and pipeline data. The DCF underscores large upside if risks resolve, but does not change the near-term risk/reward assessment.